Verve Therapeutics Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Jul '25 Jul 29, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2020
Debt / Equity Ratio	2.14	2.14	2.33	2.99	2.71	6.45	Upgrade
Debt / EBITDA Ratio	3.75	3.75	3.96	5.89	4.24	12.44	Upgrade
Debt / FCF Ratio	-	-	-	-	7.13	-	Upgrade
Asset Turnover	1.06	1.06	1.21	1.62	1.67	0.78	Upgrade
Inventory Turnover	4.93	4.93	5.36	6.95	6.76	3.66	Upgrade
Quick Ratio	0.58	0.58	0.87	0.79	0.90	0.89	Upgrade
Current Ratio	1.35	1.35	1.22	1.23	1.35	1.51	Upgrade
Return on Equity (ROE)	24.86%	24.86%	30.54%	10.80%	19.90%	13.79%	Upgrade
Return on Assets (ROA)	8.95%	8.95%	8.36%	4.51%	5.46%	3.38%	Upgrade
Return on Capital (ROIC)	10.29%	10.29%	9.61%	5.72%	6.71%	3.68%	Upgrade
Return on Capital Employed (ROCE)	26.00%	26.00%	27.20%	13.30%	14.10%	6.20%	Upgrade
Buyback Yield / Dilution	-87.00%	-7.41%	-3.36%	-65.96%	-1.50%	-	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.